Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI vs Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT03671252Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2018
- Primary completion
- Sep 2025
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of fluorouracil, folinic acid, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rectal cancer, sponsored by Sun Yat-sen University. Started Nov 2018; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03671252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671252.